184 related articles for article (PubMed ID: 30553274)
1. LARGE expression in different types of muscular dystrophies other than dystroglycanopathy.
Balci-Hayta B; Talim B; Kale G; Dincer P
BMC Neurol; 2018 Dec; 18(1):207. PubMed ID: 30553274
[TBL] [Abstract][Full Text] [Related]
2. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
3. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
Buysse K; Riemersma M; Powell G; van Reeuwijk J; Chitayat D; Roscioli T; Kamsteeg EJ; van den Elzen C; van Beusekom E; Blaser S; Babul-Hirji R; Halliday W; Wright GJ; Stemple DL; Lin YY; Lefeber DJ; van Bokhoven H
Hum Mol Genet; 2013 May; 22(9):1746-54. PubMed ID: 23359570
[TBL] [Abstract][Full Text] [Related]
4. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
Elife; 2023 Feb; 12():. PubMed ID: 36723429
[TBL] [Abstract][Full Text] [Related]
5. TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.
Larson AA; Baker PR; Milev MP; Press CA; Sokol RJ; Cox MO; Lekostaj JK; Stence AA; Bossler AD; Mueller JM; Prematilake K; Tadjo TF; Williams CA; Sacher M; Moore SA
Skelet Muscle; 2018 May; 8(1):17. PubMed ID: 29855340
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.
Longman C; Brockington M; Torelli S; Jimenez-Mallebrera C; Kennedy C; Khalil N; Feng L; Saran RK; Voit T; Merlini L; Sewry CA; Brown SC; Muntoni F
Hum Mol Genet; 2003 Nov; 12(21):2853-61. PubMed ID: 12966029
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.
Yu M; He Y; Wang K; Zhang P; Zhang S; Hu H
Hum Gene Ther; 2013 Mar; 24(3):317-30. PubMed ID: 23379513
[TBL] [Abstract][Full Text] [Related]
8. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies.
Brockington M; Muntoni F
Acta Myol; 2005 Dec; 24(3):217-21. PubMed ID: 16629056
[TBL] [Abstract][Full Text] [Related]
9. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
10. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan.
Stevens E; Carss KJ; Cirak S; Foley AR; Torelli S; Willer T; Tambunan DE; Yau S; Brodd L; Sewry CA; Feng L; Haliloglu G; Orhan D; Dobyns WB; Enns GM; Manning M; Krause A; Salih MA; Walsh CA; Hurles M; Campbell KP; Manzini MC; ; Stemple D; Lin YY; Muntoni F
Am J Hum Genet; 2013 Mar; 92(3):354-65. PubMed ID: 23453667
[TBL] [Abstract][Full Text] [Related]
11. LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy.
Goddeeris MM; Wu B; Venzke D; Yoshida-Moriguchi T; Saito F; Matsumura K; Moore SA; Campbell KP
Nature; 2013 Nov; 503(7474):136-40. PubMed ID: 24132234
[TBL] [Abstract][Full Text] [Related]
12. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies.
Cirak S; Foley AR; Herrmann R; Willer T; Yau S; Stevens E; Torelli S; Brodd L; Kamynina A; Vondracek P; Roper H; Longman C; Korinthenberg R; Marrosu G; Nürnberg P; ; Michele DE; Plagnol V; Hurles M; Moore SA; Sewry CA; Campbell KP; Voit T; Muntoni F
Brain; 2013 Jan; 136(Pt 1):269-81. PubMed ID: 23288328
[TBL] [Abstract][Full Text] [Related]
13. Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation.
Shelton GD; Minor KM; Guo LT; Friedenberg SG; Cullen JN; Hord JM; Venzke D; Anderson ME; Devereaux M; Prouty SJ; Handelman C; Campbell KP; Mickelson JR
Neuromuscul Disord; 2021 Nov; 31(11):1169-1178. PubMed ID: 34654610
[TBL] [Abstract][Full Text] [Related]
14. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
15. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies.
Barresi R; Michele DE; Kanagawa M; Harper HA; Dovico SA; Satz JS; Moore SA; Zhang W; Schachter H; Dumanski JP; Cohn RD; Nishino I; Campbell KP
Nat Med; 2004 Jul; 10(7):696-703. PubMed ID: 15184894
[TBL] [Abstract][Full Text] [Related]
16. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.
Beltrán D; Anderson ME; Bharathy N; Settelmeyer TP; Svalina MN; Bajwa Z; Shern JF; Gultekin SH; Cuellar MA; Yonekawa T; Keller C; Campbell KP
Skelet Muscle; 2019 May; 9(1):11. PubMed ID: 31054580
[TBL] [Abstract][Full Text] [Related]
17. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
18. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.
Yoshida-Moriguchi T; Yu L; Stalnaker SH; Davis S; Kunz S; Madson M; Oldstone MB; Schachter H; Wells L; Campbell KP
Science; 2010 Jan; 327(5961):88-92. PubMed ID: 20044576
[TBL] [Abstract][Full Text] [Related]
19. Glycosylation defects in muscular dystrophies.
Haliloğlu G; Topaloğlu H
Curr Opin Neurol; 2004 Oct; 17(5):521-7. PubMed ID: 15367856
[TBL] [Abstract][Full Text] [Related]
20. N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.
Crowe KE; Shao G; Flanigan KM; Martin PT
J Neuromuscul Dis; 2016 May; 3(2):247-260. PubMed ID: 27854211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
